Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC versus HEMADY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC versus HEMADY.
AMINOCAPROIC vs HEMADY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation and, to a lesser extent, noncompetitive inhibition of plasmin, thereby preventing fibrinolysis and promoting clot stability.
HEMADY is a phytonadione (vitamin K1) formulation that promotes hepatic synthesis of clotting factors II, VII, IX, and X, reversing anticoagulation by inhibiting vitamin K epoxide reductase.
4-5 g orally or intravenously as a loading dose, followed by 1 g/hour continuous infusion or 1 g every 4-6 hours orally. Maximum dose 30 g/day.
Adult: 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged to 4–10 hours in renal impairment. Clinically, dosing interval must be adjusted in renal dysfunction to avoid accumulation.
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal elimination half-life is 1.2-2 hours in healthy adults; clinically relevant as it requires frequent dosing (every 4-6 hours) for sustained effect.
Primarily renal (>95%) as unchanged drug via glomerular filtration and tubular secretion. Less than 1% biliary/fecal.
Primarily renal excretion of unchanged drug (70-80%), with 20-30% metabolized and excreted as inactive metabolites in urine; less than 5% eliminated in feces via biliary secretion.
Category C
Category C
Antifibrinolytic
Antifibrinolytic